Immunohistochemical detection of somatostatin receptors in human ovarian tumors.

Abstract:

OBJECTIVE:It is well established that many human tumors can express somatostatin receptors. This is the molecular basis for the application of long-acting somatostatin analogues for therapeutic and diagnostic purposes. However, there are discrepancies in earlier studies regarding the prevalence of somatostatin receptor expression in human ovarian tumors detected using autoradiographic binding studies or reverse transcription-polymerase chain reaction. METHODS:We have previously developed a panel of somatostatin receptor subtype-specific antibodies that effectively stain formalin-fixed, paraffin-embedded human tumor tissue. In the present study, we have used these antibodies to determine the somatostatin receptor status of 47 randomly selected human ovarian tumors. RESULTS:Somatostatin receptor-like immunoreactivity was in most cases located at the plasma membrane as well as in the cytoplasm of the tumor cells and was completely blocked with antigenic peptide. The pattern of expression of somatostatin receptor subtypes varied greatly between individual tumors. Of the 47 ovarian tumor specimens analyzed, 9 tumors (approximately 19%) were positive for sst(1), 13 (approximately 28%) revealed immunoreactive sst(2A) receptors, 20 (approximately 42%) showed sst(3)-like immunoreactivity, 8 (approximately 17%) revealed immunoreactive sst(4) receptors, and 10 (approximately 21%) were positive for sst(5). Whereas 18 tumors (approximately 38%) revealed no somatostatin receptor immunoreactive staining, 14 (approximately 30%) expressed more than one somatostatin receptor subtype. The expression of somatostatin receptor subtypes was independent of patient age, diagnosis, and histological grade. CONCLUSION:We provide direct evidence of somatostatin receptor protein expression in human ovarian tumors. Our findings suggest that a subgroup of receptor-positive ovarian tumors may be a potential target for treatment with somatostatin receptor subtype-selective analogs. However, due to the wide variations in the somatostatin receptor status of similar cases, each tumor specimen must be tested individually for the presence of particular somatostatin receptor subtypes.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Schulz S,Schmitt J,Quednow C,Roessner A,Weise W

doi

10.1006/gyno.2001.6468

subject

Has Abstract

pub_date

2002-02-01 00:00:00

pages

235-40

issue

2

eissn

0090-8258

issn

1095-6859

pii

S0090825801964686

journal_volume

84

pub_type

杂志文章
  • Trends among gynecologic oncology inpatient deaths: is end-of-life care improving?

    abstract:OBJECTIVE:The objective was to describe trends over time in key factors surrounding end-of-life care on a gynecologic oncology service at a tertiary cancer center. METHODS:Patients with gynecologic cancers who were hospitalized and died at our institution between 1992 and 1997 were identified using institutional datab...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2002.6616

    authors: Dalrymple JL,Levenback C,Wolf JK,Bodurka DC,Garcia M,Gershenson DM

    更新日期:2002-05-01 00:00:00

  • Analysis of common variations in tumor-suppressor genes on chr1p36 among Caucasian women with endometriosis.

    abstract:OBJECTIVE:Epidemiological data indicate that endometriosis increases the risk of epithelial ovarian cancer (EOC), but the mechanism of cancer transition is unknown. Results from genome-wide association studies (GWAS) and transcriptome sequencing have demonstrated that genes located in the 1p36 region are important in b...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.08.013

    authors: Falconer H,Sundqvist J,Xu H,Vodolazkaia A,Fassbender A,Kyama C,Bokor A,D'Hooghe TM

    更新日期:2012-11-01 00:00:00

  • Facts, misconceptions, and myths about cancer. What do patients with gynecological cancer and the female public at large know?

    abstract:UNLABELLED:Misconceptions about cancer may increase the level of fear in the general public and render coping more difficult in cancer patients. The aim of this survey was to study the level of knowledge and misconceptions. MATERIALS AND METHODS:A questionnaire comprising 27 questions related to cancer etiology, treat...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1997.4626

    authors: Carlsson ME,Strang PM

    更新日期:1997-04-01 00:00:00

  • HPV vaccine: A comparison of attitudes and behavioral perspectives between Latino and non-Latino women.

    abstract:OBJECTIVE:Recent scientific advances have lead to the development of a prophylactic, quadrivalent HPV vaccine conferring. We surveyed Latino and non-Latino women directly to examine what motivates them to vaccinate themselves, their daughters, and their sons. METHODS:A written survey was administered to 86 Latinas and...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.12.010

    authors: Watts LA,Joseph N,Wallace M,Rauh-Hain JA,Muzikansky A,Growdon WB,del Carmen MG

    更新日期:2009-03-01 00:00:00

  • Reproducibility in the assessment of postmenopausal ovaries with transvaginal ultrasound.

    abstract:OBJECTIVE:The goal of this study was to evaluate the interexaminer variation in the assessment of postmenopausal ovaries using transvaginal ultrasound (TVU). METHODS:One hundred eighty-eight cancer screening trial participants undergoing TVU were reassessed by a second TVU examination. RESULTS:Although first examiner...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2000.5785

    authors: Modugno F,Weissfeld JL,Hill LM

    更新日期:2000-05-01 00:00:00

  • Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal pap smears before colposcopy referral.

    abstract:OBJECTIVE:The purpose of this work was to evaluate the ability of testing for high-risk human papillomavirus (HPV) types using the hybrid capture technique to predict the presence of cervical intraepithelial neoplasia (CIN) II,III in patients with repeated atypical squamous cells of undetermined significance (ASCUS) an...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1006/gyno.2000.5929

    authors: Fait G,Kupferminc MJ,Daniel Y,Geva E,Ron IG,Lessing JB,Bar-Am A

    更新日期:2000-11-01 00:00:00

  • Update on novel therapeutic agents for cervical cancer.

    abstract::Effective cytotoxic treatment options for advanced cervical cancer are exceedingly limited. Cisplatin-based combination chemotherapy, the most commonly used cytotoxic therapy, has produced response rates ranging from 20% to 30% and overall survival of less than 10 months. Because of the minimal degree of success with ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2008.04.016

    authors: del Campo JM,Prat A,Gil-Moreno A,Pérez J,Parera M

    更新日期:2008-09-01 00:00:00

  • Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.

    abstract:OBJECTIVE:The first-line chemotherapy for ovarian cancer is based on a combination of platinum and taxane. To date, no reliable predictive biomarker has been recognized that is capable of identifying patients with pre-existing resistance to these agents. Here, we have established an integrated database and identified t...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.01.006

    authors: Fekete JT,Ősz Á,Pete I,Nagy GR,Vereczkey I,Győrffy B

    更新日期:2020-03-01 00:00:00

  • Recurrent metastatic fallopian tube carcinoma in pregnancy.

    abstract:BACKGROUND:Fallopian tube cancer is the rarest of all gynecologic cancers. An extensive literature search on Medline reveals no previous case reports of fallopian tube carcinoma in association with a term pregnancy. CASE:A woman with surgical stage IIB fallopian tube carcinoma was treated with limited staging laparoto...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2000.6097

    authors: Adolph A,Le T,Khan K,Biem S

    更新日期:2001-04-01 00:00:00

  • Real-time near-infrared fluorescence guided surgery in gynecologic oncology: a review of the current state of the art.

    abstract::Near-infrared (NIR) fluorescence imaging has emerged as a promising complimentary technique for intraoperative visualization of tumor tissue, lymph nodes and vital structures. In this review, the current applications and future opportunities of NIR fluorescence imaging in gynecologic oncology are summarized. Several s...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2014.08.005

    authors: Handgraaf HJ,Verbeek FP,Tummers QR,Boogerd LS,van de Velde CJ,Vahrmeijer AL,Gaarenstroom KN

    更新日期:2014-12-01 00:00:00

  • Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.

    abstract:OBJECTIVE:Overexpression of the tyrosine kinase receptor erbB-2 is important in the pathogenesis of a variety of neoplasms including ovarian cancer. As a strategy to selectively eradicate erbB-2-overexpressing tumor cells, an anti-erbB-2 single-chain immunoglobin (sFv) gene was constructed to direct expression of intra...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1995.1260

    authors: Deshane J,Cabrera G,Grim JE,Siegal GP,Pike J,Alvarez RD,Curiel DT

    更新日期:1995-10-01 00:00:00

  • Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study.

    abstract:PURPOSE:To determine overall survival and progression-free survival among patients with high-risk, stage III and IV endometrial cancer who receive paclitaxel and carboplatin (TC) after complete tumor resection. PATIENTS AND METHODS:Patients with stage III/IV endometrial cancer with less than 2 cm of disease after surg...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.03.019

    authors: Sovak MA,Hensley ML,Dupont J,Ishill N,Alektiar KM,Abu-Rustum N,Barakat R,Chi DS,Sabbatini P,Spriggs DR,Aghajanian C

    更新日期:2006-11-01 00:00:00

  • Evaluation of the performance of the ACS NSQIP surgical risk calculator in gynecologic oncology patients undergoing laparotomy.

    abstract:OBJECTIVE:The objective of this study was to evaluate the ability of the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) surgical risk calculator to predict complications in gynecologic oncology patients undergoing laparotomy. METHODS:A chart review of patients who underwent la...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2016.02.015

    authors: Rivard C,Nahum R,Slagle E,Duininck M,Isaksson Vogel R,Teoh D

    更新日期:2016-05-01 00:00:00

  • A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

    abstract:PURPOSE:Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced, ovarian cancer. However, the role of IP therapy in recurrent disease is unknown. Preclinical data demonstrated IP administration of the proteasome inhibitor, bortezomib pr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2017.03.013

    authors: Jandial DA,Brady WE,Howell SB,Lankes HA,Schilder RJ,Beumer JH,Christner SM,Strychor S,Powell MA,Hagemann AR,Moore KN,Walker JL,DiSilvestro PA,Duska LR,Fracasso PM,Dizon DS

    更新日期:2017-05-01 00:00:00

  • Choriocarcinoma in a term placenta with maternal metastases.

    abstract::Choriocarcinoma of the nonmolar placenta is presumptively a rare entity and is usually associated with widespread maternal metastases at the time of diagnosis. Nonmetastatic disease goes unrecognized and undiagnosed because placental carcinoma can be limited to a few villi, and grossly evident disease is often misinte...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/0090-8258(92)90264-j

    authors: Christopherson WA,Kanbour A,Szulman AE

    更新日期:1992-08-01 00:00:00

  • Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.

    abstract:OBJECTIVE:Primary objective of this study was to determine prognostic significance of Bohm's histopathological regression score in patients who received neoadjuvant chemotherapy (NACT) for treatment of high grade serous (HGS) tubal & ovarian carcinoma. METHODS:This was a retrospective cohort study of patients who rece...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.08.042

    authors: Rajkumar S,Polson A,Nath R,Lane G,Sayasneh A,Jakes A,Begum S,Mehra G

    更新日期:2018-11-01 00:00:00

  • Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.

    abstract:OBJECTIVE:In this phase II study the efficacy and toxicity of an alternating chemotherapy regimen was examined in platinum-resistant relapsed epithelial ovarian cancer (EOC) patients. METHODS:Forty-five patients with platinum-refractory/resistant relapsed EOC, previously treated with carboplatin+paclitaxel+/-epirubici...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.03.003

    authors: Pectasides D,Pectasides E,Papaxoinis G,Psyrri A,Pliarchopoulou K,Koumarianou A,Macheras A,Athanasas G,Xiros N,Economopoulos T

    更新日期:2010-07-01 00:00:00

  • Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?

    abstract:OBJECTIVE:Given the paucity of data regarding the patterns of metastasis from ovarian sex cord-stromal tumors (SCSTs), we sought to determine the risk of lymph node metastasis in patients with SCSTs. METHODS:A retrospective chart review was performed after clinical and pathology databases were queried for ovarian SCST...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.12.007

    authors: Brown J,Sood AK,Deavers MT,Milojevic L,Gershenson DM

    更新日期:2009-04-01 00:00:00

  • ABC transporter gene expression in benign and malignant ovarian tissue.

    abstract:OBJECTIVE:ATP-binding Cassette (ABC) transporters are thought to cause multiple drug resistance (MDR) in various carcinomas. Gene expression data from individual transporters in ovarian cancer tissue is contradictory and also scarce for some of them. RNA levels of a panel of ABC transporters were collected and analyzed...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.10.077

    authors: Auner V,Sehouli J,Oskay-Oezcelik G,Horvat R,Speiser P,Zeillinger R

    更新日期:2010-05-01 00:00:00

  • "MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer.

    abstract::Twenty-nine women, ages 30-58 years, with advanced ovarian carcinoma were treated with a developmental combination chemotherapy regimen consisting of mitomycin C, etoposide, cisplatin, and carboplatin (MECCA). This protocol utilized the concepts of dose intensity, front-end loading, non-cross-resistance, and synergy. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1996.0334

    authors: Hoskins PJ,Swenerton KD,Pike JA,McMurtrie EM,Lee N

    更新日期:1996-12-01 00:00:00

  • Role of toll-like receptors in cervical, endometrial and ovarian cancers: a review.

    abstract:OBJECTIVE:The Toll-like receptors (TLRs) have been implicated in inflammation, innate immunity and cancer. The goal of this paper is to review the available published research about Toll-like receptors and their roles in gynecologic malignancies. METHODS:A Medline search was conducted and published articles from the l...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2014.08.013

    authors: Husseinzadeh N,Davenport SM

    更新日期:2014-11-01 00:00:00

  • Epigenetics of ovarian cancer: from the lab to the clinic.

    abstract:OBJECTIVE:Ovarian cancer remains the most lethal gynaecological cancer. Various molecular changes have been identified and have shown promise for their diagnostic, prognostic and curative capacity but still need further validation. Among different mechanisms, the present article reviews the importance of epigenetic cha...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2010.03.015

    authors: Asadollahi R,Hyde CA,Zhong XY

    更新日期:2010-07-01 00:00:00

  • A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.

    abstract:OBJECTIVE:The mTOR inhibitor, temsirolimus, has clinical activity in the treatment of gynecologic malignancies, particularly endometrial cancer. We sought to determine the tolerability of the combination of weekly topotecan with weekly temsirolimus. METHODS:Women with a history of advanced or recurrent gynecologic mal...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.02.022

    authors: Temkin SM,Yamada SD,Fleming GF

    更新日期:2010-06-01 00:00:00

  • Pilomatricoma-like endometrioid adenosquamous carcinoma of the ovary with neuroendocrine differentiation.

    abstract::A case of high-grade endometrioid adenosquamous carcinoma of the ovary showing pilomatricoma-like areas and neuroendocrine differentiation is presented. The pilomatricoma-like areas were strongly positive for cytokeratin and vimentin, whereas the poorly differentiated areas of the tumor were positive for cytokeratin, ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1996.0142

    authors: Fang J,Keh P,Katz L,Rao MS

    更新日期:1996-05-01 00:00:00

  • Chemotherapy and extended-field radiation therapy to para-aortic area in patients with histologically proven metastatic cervical cancer to para-aortic nodes: a phase II pilot study.

    abstract::From November 1983 to October 1992, 22 patients with invasive cervical cancer stage IB through stage IIIB with metastasis to para-aortic nodes were entered in this study. Five patients were excluded. Of 17 remaining evaluable patients, 5 (29%) were stage IB, 6 (35%) were stage IIB, and 6 (35%) were stage IIIB. Four (2...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1006/gyno.1994.1057

    authors: Husseinzadeh N,Shrake P,DeEulis T,Rowley K,Aron B

    更新日期:1994-03-01 00:00:00

  • Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition.

    abstract:OBJECTIVE:Neuropilin-1 (NRP-1) is a receptor for both semaphorin and vascular endothelial growth factor and is up-regulated in a variety of human cancers. While there are some reports of NRP-1 expression in ovarian neoplasm, those results differ in pattern of its expression and its role in ovarian cancer is still uncle...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.02.005

    authors: Baba T,Kariya M,Higuchi T,Mandai M,Matsumura N,Kondoh E,Miyanishi M,Fukuhara K,Takakura K,Fujii S

    更新日期:2007-06-01 00:00:00

  • Management of patients with metastatic gestational trophoblastic tumor.

    abstract:OBJECTIVE:This study was designed to analyze the results of treatment on patients with metastatic gestational trophoblastic tumor (metastatic GTT). METHOD:During 1996-2001, 38 cases with metastatic GTT were diagnosed and received treatment in Vali-e-Asr Hospital, Tehran, Iran. Data were gathered retrospectively and an...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.04.006

    authors: Ghaemmaghami F,Behtash N,Soleimani K,Hanjani P

    更新日期:2004-07-01 00:00:00

  • Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?

    abstract:OBJECTIVES:The objective of this study was to determine whether the length of the interval from primary surgery to commencement of chemotherapy has any direct effect on progression-free survival in ovarian cancer. METHODS:The progression-free survival of 472 patients enrolled in four trials who had all received platin...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2002.6750

    authors: Flynn PM,Paul J,Cruickshank DJ,Scottish Gynaecological Cancer Trials Group.

    更新日期:2002-09-01 00:00:00

  • A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.

    abstract:OBJECTIVE:We performed a phase I, single-arm, non-randomized, open-label, dose-escalation trial to determine the dose-limiting toxicity of intraperitoneal cisplatin and doxorubicin applied as pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with recurrent ovarian cancer. METHODS:We used a standard 3 +...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.05.001

    authors: Tempfer CB,Giger-Pabst U,Seebacher V,Petersen M,Dogan A,Rezniczek GA

    更新日期:2018-07-01 00:00:00

  • Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors.

    abstract:OBJECTIVE:The aberrant expression of hepatocyte growth factor and its receptor c-Met are associated with aggressive disease and poor prognosis in a variety of human malignancies including ovarian cancer (OC). Specificity protein (Sp) transcription factors have high relevance in the signaling cascade associated with c-M...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.03.014

    authors: Basha R,Ingersoll SB,Sankpal UT,Ahmad S,Baker CH,Edwards JR,Holloway RW,Kaja S,Abdelrahim M

    更新日期:2011-07-01 00:00:00